Related Experiment Video

Updated: Jan 2, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

502

Pediatric-inspired protocols in adult acute lymphoblastic leukemia: are the results bearing fruit?

Lori Muffly1, Emily Curran2

  • 1Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University, Stanford, CA; and.

Hematology. American Society of Hematology. Education Program
|December 7, 2019
PubMed

Insights

Younger adults with acute lymphoblastic leukemia (ALL) show improved survival using pediatric regimens. While feasible and superior to adult regimens, this approach has increased toxicities and requires careful minimal residual disease (MRD) monitoring.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Trials

Background:

  • Acute lymphoblastic leukemia (ALL) treatment in young adults historically yielded poorer outcomes compared to children.
  • Adult-specific chemotherapy regimens for ALL have shown limited efficacy in this demographic.

Observation:

  • Observational studies noted better survival rates in young adults treated with pediatric ALL regimens.
  • This led to prospective trials evaluating the pediatric approach in adult ALL patients.

Findings:

  • International trials confirmed the feasibility and superiority of pediatric ALL regimens in young adults compared to historical adult regimens.
  • Increased prevalence of specific toxicities like thrombosis, hepatotoxicity, and osteonecrosis was observed in adults on pediatric regimens.
  • Persistent minimal residual disease (MRD) emerged as a significant negative prognostic factor.

Implications:

  • Pediatric ALL regimens are a viable and superior treatment option for young adults with ALL.
  • Close monitoring for specific toxicities and sensitive MRD evaluation are crucial for this patient population.
  • Future research should focus on integrating targeted agents to further enhance outcomes, especially in the MRD-positive setting.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.5K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.3K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
177
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
214
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
200
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
155
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
781